Mercaptopurine Tablets
Recall D-0367-2024, part of FDA recall event 93960. See Stason Pharmaceuticals's company page.
Stason Pharmaceuticals, Inc. started this Class III drug recall on Feb 9, 2024 (voluntary: firm initiated); FDA lists it as terminated, terminated Feb 5, 2026.
- Classification: Class III
- Started: Feb 9, 2024
- Status: Terminated
Failed Dissolution Specifications: results slightly under spec at at 9-months.
- Product
- Mercaptopurine Tablets, USP 50 mg, packaged in: a) 25-count bottle (NDC 69076-913-02), b) 250-count bottle (NDC 69076-913-25), Rx only, Manufactured for: Quinn Pharmaceuticals, Boca Raton, FL, www.quinnrx.com
- Quantity
- 54, 131 bottles
- Lots and codes
- Lot #: a)22K012, 22K013A, Exp: 04/30/2024; 23A001, 23A002A, Exp: 07/31/2024; 23D006, 23D007A, 23D007C, Exp:10/31/2024; b)22K013B, Exp: 04/30/2024; 23A002B, Exp:07/31/2024; 23D007B, Exp: 10/31/2024.
- Distribution
- USA Nationwide
- Recalling firm
- Stason Pharmaceuticals, Inc., Irvine, CA, United States
- How the firm notified
- Letter
- FDA classified
- Mar 6, 2024
Newest first, one product per recall event; search them all
- Selegiline HCL Tablets USP 5mg, 60- count bottles, Rx only, Manufactured by: Stason Pharmaceuticals, Inc. Irvine, CA…D-1479-2016 · Class III · Aug 23, 2016 · Terminated
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports